In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Actuate Therapeutics Inc (NASDAQ: ACTU) closed at $5.96 up 2.41% from its previous closing price of $5.82. In other words, the price has increased by $2.41 from its previous closing price. On the day, 0.95 million shares were traded. ACTU stock price reached its highest trading level at $6.5 during the session, while it also had its lowest trading level at $5.5.
Ratios:
For a deeper understanding of Actuate Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.46 and its Current Ratio is at 0.46.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on April 22, 2025, initiated with a Buy rating and assigned the stock a target price of $21.
On March 17, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $20.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 14 ’24 when THOMSON TODD S sold 18,750 shares for $8.00 per share. The transaction valued at 150,000 led to the insider holds 1,184,795 shares of the business.
Bios Equity COF, LP bought 500,000 shares of ACTU for $4,000,000 on Aug 14 ’24. The Director now owns 1,259,427 shares after completing the transaction at $8.00 per share. On Aug 14 ’24, another insider, Bios Equity COF, LP, who serves as the Director of the company, sold 24,999 shares for $9.00 each. As a result, the insider received 224,991 and left with 131,248 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACTU now has a Market Capitalization of 116933416 and an Enterprise Value of 113043768.
Stock Price History:
Over the past 52 weeks, ACTU has reached a high of $11.99, while it has fallen to a 52-week low of $5.51. The 50-Day Moving Average of the stock is -34.64%, while the 200-Day Moving Average is calculated to be -27.77%.
Shares Statistics:
For the past three months, ACTU has traded an average of 67.73K shares per day and 194990 over the past ten days. A total of 19.53M shares are outstanding, with a floating share count of 5.90M. Insiders hold about 69.92% of the company’s shares, while institutions hold 2.59% stake in the company. Shares short for ACTU as of 1749772800 were 241372 with a Short Ratio of 3.56, compared to 1747267200 on 198285. Therefore, it implies a Short% of Shares Outstanding of 241372 and a Short% of Float of 3.95.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Actuate Therapeutics Inc (ACTU) is the result of assessments by 2 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.3, with high estimates of -$0.28 and low estimates of -$0.32.
Analysts are recommending an EPS of between -$1.2 and -$1.31 for the fiscal current year, implying an average EPS of -$1.25. EPS for the following year is -$1.33, with 3.0 analysts recommending between -$0.98 and -$1.67.
